Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
11 hedge funds and large institutions have $92.2M invested in Evofem Biosciences, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
15,666% more capital invested
Capital invested by funds: $585K → $92.2M (+$91.6M)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
38% more funds holding
Funds holding: 8 → 11 (+3)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$63.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$60.2M |
| 3 |
Millennium Management
New York
|
+$95.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$52.7K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$15.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$521K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$20K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.96K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4K |
| 5 |
BlackRock
New York
|
-$2.31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WIM
1
Woodford Investment Management
London,
United Kingdom
| $47.4M | +$63.9M | +497,703 | New |
|
|
2
Invesco
Atlanta,
Georgia
| $44.7M | +$60.2M | +469,167 | New |
|
|
3
Millennium Management
New York
| $71K | +$95.1K | +741 | New |
|
|
PAM
4
Panagora Asset Management
Boston,
Massachusetts
| $39K | +$52.7K | +411 | New |
|
|
5
Bank of America
Charlotte,
North Carolina
| $12K | +$15.9K | +124 | New |
|
|
6
BlackRock
New York
| $8K | -$2.31K | -18 | -19% |
|
|
WAS
7
WESPAC Advisors SoCal
Pasadena,
California
| $3K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $2K | -$7.96K | -62 | -74% |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$898 | +7 | +64% |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
11
Parallax Volatility Advisers
San Francisco,
California
| $1K | +$1.28K | +10 | New |
|
|
12
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$521K | -2,971 | Closed |
|
|
13
Northern Trust
Chicago,
Illinois
| – | -$20K | -115 | Closed |
|
|
14
Vanguard Group
Malvern,
Pennsylvania
| – | -$4K | -20 | Closed |
|
EVFM Hedge Fund Activity: Q1 2018 in Review
11 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2018, worth a combined $92.2M — up 15,666% from $585K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EVFM positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Woodford Investment Management, opening a new position worth an estimated $63.9M. The largest seller was Deutsche Bank, exiting entirely with an estimated $521K sold.
- 11 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2018, up from 8 in Q4 2017.
- Funds reported $92.2M of Evofem Biosciences, Inc. Common Stock stock for Q1 2018, up 15,666% quarter-over-quarter.
- 6 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2018 and 3 closed out, a net change of +3 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2018 was Woodford Investment Management, an estimated $63.9M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2018 was Deutsche Bank, an estimated $521K sold.
Based on aggregated 13F filings for Q1 2018.